AbbVie Inc. (ABBV): Price and Financial Metrics


AbbVie Inc. (ABBV)

Today's Latest Price: $72.67 USD

1.16 (-1.57%)

Updated Mar 27 12:00am

Add ABBV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABBV Stock Summary

  • ABBV has a higher market value than 98.66% of US stocks; more precisely, its current market capitalization is $99,805,636,646.
  • The capital turnover (annual revenue relative to shareholder's equity) for ABBV is -4.07 -- better than just 3.06% of US stocks.
  • ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 2.11% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AbbVie Inc are TXN, BMY, AMGN, GILD, and AZN.
  • Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to www.abbvie.com.
ABBV Daily Price Range
ABBV 52-Week Price Range

ABBV Stock Price Chart More Charts


ABBV Price/Volume Stats

Current price $72.67 52-week high $97.86
Prev. close $73.83 52-week low $62.55
Day low $70.71 Volume 12,293,200
Day high $75.06 Avg. volume 12,216,435
50-day MA $84.76 Dividend yield 6.5%
200-day MA $78.67 Market Cap 107.31B

AbbVie Inc. (ABBV) Company Bio


Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$72.67$209.97184%

We started the process of determining a valid price forecast for AbbVie Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that AbbVie Inc ranked in the 67th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 185.83% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of AbbVie Inc, consider:

  • The company's balance sheet shows it gets 62% of its capital from equity, and 38% of its capital from debt. Its equity weight surpasses that of merely 20.94% of free cash flow generating stocks in the Healthcare sector.
  • AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 10.56% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%179%
1%182%
2%184%
3%187%
4%190%
5%193%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ABBV, try NVO, SEM, JAZZ, AGN, and HCA.


ABBV Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ABBV Latest Social Stream


Loading social stream, please wait...

View Full ABBV Social Stream

ABBV Price Returns

1-mo -15.21%
3-mo -16.80%
6-mo 2.04%
1-year -4.61%
3-year 26.74%
5-year 52.42%
YTD -16.82%
2019 1.47%
2018 -0.96%
2017 60.07%
2016 9.79%
2015 -6.50%

ABBV Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7643 seconds.